The pivotal trial of mavacamten is the first in a wave of emerging data from studies of treatment of various forms of hypertrophic cardiomyopathy. We outline the findings to come.Read More
A panel of clinicians has outlined strategies for closing well-established gaps in cardiovascular care delivery for Black women. We share takeaways from a co-author and other clinicians with expertise in care equity.
A new study details the generalizable measures we took to significantly reduce radiation exposure for catheterization lab personnel and patients.
LEADconnection.org is a new, freely accessible website designed to promote information exchange around best practices and research in the use of CIEDs and lead management.
Lifelong surveillance is paramount for adults with congenital heart disease. This upcoming CME event aims to ensure awareness and utilization of advances in imaging, surgical repair and catheter interventions.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
For adults with pulmonary valve dysfunction who have had prior open-heart surgeries, more transcatheter options are available than ever before.
Randomized trial evidence that weight loss can yield cardiovascular benefits independent of antidiabetic effects has been elusive. Two major ongoing trials are likely to change that, with potentially big implications for clinical practice.
A broad research effort involving network-medicine methodologies and pharmacoepidemiologic analysis has pinpointed the diabetes medication metformin as a leading antiarrhythmic candidate drug.
In-hospital mortality following LAAC was no higher in patients aged 80 or older than in their younger counterparts, a large database analysis shows. We share insights on LAAC in this population from the Cleveland Clinic experience.
The myosin inhibitor yields improvements in measure of diastolic function independent of effects on left ventricular outflow tract gradients and mitral regurgitation, a new subanalysis finds.
A novel soft robotic device designed to fit around the ascending aorta promises to enable high-fidelity simulation of the hemodynamics and biomechanics of aortic stenosis and congenital valve disease.